New tech transforms drug discovery & delivery.

Sofia Petrova*

Department of Pharmaceutical Chemistry, Moscow State University, Russia

Introduction

Targeting intrinsically disordered proteins (IDPs) in drug discovery is a significant area of research, particularly given their involvement in various diseases. The conformational flexibility of IDPs presents unique challenges, pushing the development of advanced computational and experimental methods to create new therapeutic approaches for these complex targets [1].

In drug delivery, lipid-based nanocarriers have seen considerable progress. These systems, including liposomes, solid lipid nanoparticles, and nanostructured lipid carriers, offer advantages like enhanced bioavailability, targeted delivery, and reduced toxicity. They show great promise for advanced drug formulation across diverse therapeutic applications [2].

Fragment-based drug discovery (FBDD) benefits immensely from a computational perspective. This approach identifies and optimizes small molecular fragments to construct potent drug candidates. Computational techniques such as docking, molecular dynamics, and free energy calculations accelerate FBDD by predicting fragment binding and guiding lead optimization [3].

Cryo-Electron Microscopy (Cryo-EM) is making a growing impact in drug discovery. This technology provides high-resolution structural insights into challenging drug targets, including large protein complexes and membrane proteins. These insights are crucial for rational drug design and accelerate the development of novel therapeutics [4].

Nanotechnology plays a vital role in cancer drug delivery, though it faces ongoing advancements and hurdles. Various nanocarriers, such as liposomes, polymeric nanoparticles, and exosomes, are being explored for their ability to improve drug solubility, achieve targeted delivery, and reduce systemic toxicity in cancer treatment [5].

Artificial Intelligence (AI) and Machine Learning (ML) are being integrated into virtual screening methodologies for drug discovery. These technologies significantly enhance the efficiency and accuracy of identifying potential drug candidates from vast chemical libraries, thereby accelerating hit identification and lead optimization processes [6].

Innovations in pharmaceutical excipients are crucial for improving drug solubility and bioavailability, key factors in effective drug formulation. Research details various excipients and their mechanisms, demonstrating how they address challenges with poorly soluble drugs and boost therapeutic efficacy [7].

Deep learning applications are expanding across multiple stages of drug discovery, from target identification to lead optimization. These advanced computational techniques speed up the process by predicting molecular properties, facilitating de novo drug design, and improving compound screening efficiency [8].

Understanding protein-ligand interactions is critical for both rational drug design and effective drug formulation. Various biophysical and computational techniques characterize these interactions, offering insights essential for optimizing drug binding affinity, specificity, and stability in formulation [9].

Computational chemistry is proving its utility in organocatalysis, particularly for elucidating reaction mechanisms and designing better catalysts. Theoretical calculations guide the development of more efficient and selective synthetic routes, significantly contributing to pharmaceutical chemistry and sustainable production of active pharmaceutical ingredients [10].

Conclusion

The landscape of drug discovery is rapidly evolving, driven by innovations across computational methods, structural biology, and advanced delivery systems. Computational approaches, including fragment-based drug discovery, Artificial Intelligence (AI), Machine Learning (ML), and deep learning, significantly accelerate the identification and optimization of drug candidates by predicting molecular properties and guiding design. Technologies like Cryo-Electron Microscopy (Cryo-EM) provide high-resolution structural insights into challenging drug targets, such as large protein complexes and membrane proteins, facilitating rational drug design. Focus is also placed on difficult targets like intrinsically disordered proteins (IDPs), where new computational and experimental meth-

***Correspondence to:** Sofia Petrova, Department of Pharmaceutical Chemistry, Moscow State University, Russia. E-mail: sofia.petrova@msu.ru

Received: 04-Sep-2025, Manuscript No. AAPCCS-25-205; **Editor assigned:** 08-Sep-2025, Pre QC No. AAPCCS-25-205 *(PQ)*; **Reviewed:** 26-Sep-2025, QC No. AAPCCS-25-205; **Revised:** 07-Oct-2025, Manuscript No. AAPCCS-25-205 *(R)*; **Published:** 16-Oct-2025, DOI: 10.35841/aapccs-9.4.205

Citation: Petrova S. New tech transforms drug discovery & delivery. J Pharm Chem Chem Sci. 2025;09(04):205.

ods are being developed to overcome their conformational flexibility for therapeutic purposes. In drug delivery, nanocarriers—including lipid-based systems, liposomes, polymeric nanoparticles, and exosomes—are enhancing bioavailability, enabling targeted delivery, and reducing toxicity, especially in areas like cancer therapy. Furthermore, advancements in pharmaceutical excipients are crucial for improving drug solubility and bioavailability, addressing challenges with poorly soluble compounds. Understanding protein-ligand interactions through biophysical and computational techniques is fundamental for optimizing drug binding and formulation stability. Computational chemistry extends its utility to synthetic processes, assisting in organocatalysis for mechanism elucidation and catalyst design, ensuring more efficient and sustainable production of pharmaceutical ingredients. Collectively, these diverse scientific and technological advancements underscore a multidisciplinary effort to develop more effective and precise therapeutic solutions.

References

1. Hongyi H, Yunhui M, Wei H. Targeting intrinsically disordered proteins for drug discovery: current strategies and future directions. *Comput Struct Biotechnol J.* 2023;21:649-659.
2. Yichen J, Qian G, Wei W. Recent advances in lipid-based nanocarriers for drug delivery: a comprehensive review. *J Control Release.* 2023;362:22-42.
3. Jing-Hui Z, Xiao-Jie J, Hao-Jie Z. Fragment-based drug discovery: *A computational perspective. RSC Adv.* 2022;12:31089-31102.
4. Xiaoxiang L, Junjie L, Jinyao L. Cryo-electron microscopy in drug discovery: *From structural insights to therapeutic development. Acta Pharm Sin B.* 2022;12(1):64-80.
5. Shuo Z, Bing X, Ruili Y. Nanotechnology-based drug delivery systems for cancer therapy: current progress and future challenges. *J Nanobiotechnology.* 2021;19(1):119.
6. Jun L, Zhibin W, Xin M. Artificial Intelligence and Machine Learning in Virtual Screening for Drug Discovery: *A Comprehensive Review. Molecules.* 2023;28(11):4407.
7. Zhi L, Jie H, *Junjie D. Recent advances in pharmaceutical excipients for enhancing drug solubility and bioavailability. J Pharm Sci.* 2021;110(12):3848-3860.
8. Xinhui Z, Peng Z, Qianqian Y. Deep learning approaches for drug discovery: current status and future perspectives. *Drug Discov Today.* 2023;28(10):103706.
9. Qiang Z, Xiaojun Z, Yongjun D. Understanding protein-ligand interactions for rational drug design and formulation. *Front Pharmacol.* 2020;11:762.
10. Zhi-Yuan S, Wei-Liang L, Lei L. Computational Chemistry in Organocatalysis: *A Powerful Tool for Mechanism Elucidation and Catalyst Design. Org Lett.* 2019;21(16):6516-6530.

Citation: *Petrova S. New tech transforms drug discovery & delivery. J Pharm Chem Chem Sci. 2025;09(04):205.*